Brimonidine Tartrate/Timolol Maleate (Page 5 of 5)
17 PATIENT COUNSELING INFORMATION
Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product [see Contraindications ( 4.1, 4.2)].
Patients should be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions or by inadvertent contact with the dropper tip [see Warnings and Precautions (5.10)]. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.
Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician’s advice concerning the continued use of the present multidose container.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
Patients should be advised that brimonidine tartrate/timolol maleate ophthalmic solution contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of brimonidine tartrate/timolol maleate ophthalmic solution.
As with other similar medications, brimonidine tartrate/timolol maleate ophthalmic solution may cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.
Manufactured In India By:
Indoco Remedies Limited
Verna, Goa 403722, India
Manufactured For:
Teva Pharmaceuticals USA, Inc.
Parsippany, NJ 07054
Iss. 2/2022
NDC 0591-2422-26
Brimonidine
Tartrate/
Timolol Maleate
Ophthalmic
Solution
0.2%/0.5%
Sterile
Rx only5 mL
BRIMONIDINE TARTRATE/TIMOLOL MALEATE brimonidine tartrate and timolol maleate solution/ drops | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
|
Labeler — Actavis Pharma, Inc. (119723554) |
Establishment | |||
Name | Address | ID/FEI | Operations |
INDOCO REMEDIES LIMITED | 915851870 | label (0591-2422), manufacture (0591-2422), pack (0591-2422) |
Revised: 02/2022 Actavis Pharma, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/brimonidine-tartratetimolol-maleate-1/page/5/